| dc.contributor.author | RECOVERY Collaborative Group | |
| dc.date.accessioned | 2022-08-02T11:23:01Z | |
| dc.date.available | 2022-08-02T11:23:01Z | |
| dc.date.issued | 2022-08-05 | |
| dc.identifier | 218527438 | |
| dc.identifier | d06596f0-c336-4ba9-a967-cd52aca88455 | |
| dc.identifier | 35908569 | |
| dc.identifier | 85135019586 | |
| dc.identifier.citation | RECOVERY Collaborative Group 2022 , ' Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY) : a randomised, controlled, open-label, platform trial and updated meta-analysis ' , The Lancet , vol. 400 , no. 10349 , pp. 359-368 . https://doi.org/10.1016/S0140-6736(22)01109-6 | en |
| dc.identifier.issn | 0140-6736 | |
| dc.identifier.other | ORCID: /0000-0002-1397-4272/work/116747541 | |
| dc.identifier.uri | https://hdl.handle.net/2164/18987 | |
| dc.description | Acknowledgments Above all, we thank the thousands of patients who participated in this trial. We also thank the many doctors, nurses, pharmacists, other allied health professionals, and research administrators at National Health Service hospital organisations across the whole of the UK, supported by staff at the National Institute of Health Research (NIHR) Clinical Research Network, NHS DigiTrials, Public Health England, Department of Health & Social Care, the Intensive Care National Audit & Research Centre, Public Health Scotland, National Records Service of Scotland, the Secure Anonymised Information Linkage at the University of Swansea, and the NHS in England, Scotland, Wales, and Northern Ireland. The RECOVERY trial is supported by grants to the University of Oxford from UK Research and Innovation and NIHR (MC_PC_19056), the Wellcome Trust (grant reference 222406/Z/20/Z) through the COVID-19 Therapeutics Accelerator, and by core funding provided by the NIHR Oxford Biomedical Research Centre, the Wellcome Trust, the Bill and Melinda Gates Foundation, the Foreign, Commonwealth and Development Office, Health Data Research UK, the Medical Research Council Population Health Research Unit, the NIHR Health Protection Unit in Emerging and Zoonotic Infections, and NIHR Clinical Trials Unit Support Funding. TJ is supported by a grant from UK Medical Research Council (MC_UU_00002/14). WSL is supported by core funding provided by NIHR Nottingham Biomedical Research Centre. Tocilizumab was provided free of charge for this trial by Roche Products. Regeneron Pharmaceuticals supported the trial through provision of casirivimab and imdevimab. Baricitinib was provided from routine NHS stock. The views expressed in this publication are those of the authors and not necessarily those of the NHS, the NIHR, or the Department of Health and Social Care. For the purpose of Open Access, the author has applied a CC BY public copyright licence to any Author Accepted Manuscript version arising from this submission. | en |
| dc.format.extent | 10 | |
| dc.format.extent | 1169005 | |
| dc.language.iso | eng | |
| dc.relation.ispartof | The Lancet | en |
| dc.subject | R Medicine | en |
| dc.subject | Medical Research Council (MRC) | en |
| dc.subject | MC_PC_19056 | en |
| dc.subject | MC_UU_00002/14 | en |
| dc.subject | National Institute for Health Research (NIHR) | en |
| dc.subject | Wellcome Trust | en |
| dc.subject | 222406/Z/20/Z | en |
| dc.subject | Supplementary Information | en |
| dc.subject.lcc | R | en |
| dc.title | Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY) : a randomised, controlled, open-label, platform trial and updated meta-analysis | en |
| dc.type | Journal article | en |
| dc.contributor.institution | University of Aberdeen.Applied Medicine | en |
| dc.description.status | Peer reviewed | en |
| dc.identifier.doi | https://doi.org/10.1016/S0140-6736(22)01109-6 | |
| dc.identifier.vol | 400 | en |
| dc.identifier.iss | 10349 | en |
